| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The compound itself has no intrinsic biological target. In ADC applications, the MC group conjugates to a thiolated antibody, while the amine group couples to a cytotoxic payload via a cleavable or non-cleavable linkage. The Val-Cit dipeptide is cleaved by cathepsin B in lysosomes, triggering self-immolation of the PAB spacer and release of the free drug. This design provides tumor-selective payload release.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
In vitro activity is characterized by efficient thiol conjugation and payload attachment and cathepsin B-mediated cleavage. The MC group reacts with thiols at pH 6.5-7.5 for 2-4 hours. The amine group reacts with NHS esters at pH 7.2-8.5 for 1-2 hours or with activated carboxylic acids. The Val-Cit dipeptide is cleaved by cathepsin B at pH 5.0-6.0. Cleavage efficiency is assessed by HPLC or LC-MS. |
| ln Vivo |
No direct in vivo biological activity is reported. Its utility arises from incorporation into ADC molecules. The Val-Cit-PAB linker is stable in plasma but efficiently cleaved in lysosomes, providing tumor-selective drug release. In vivo studies involving ADCs with this linker typically evaluate antitumor efficacy in xenograft models, with dosing via intravenous injection.
|
| Enzyme Assay |
For non-cellular binding assays, reduce antibody with TCEP at 1-5 mM for 30 minutes at room temperature. Purify by desalting column. Dissolve MC-VC-PAB-NH2 in PBS at pH 7.2-7.4 and add to reduced antibody at 2-5 fold molar excess. Incubate 2-4 hours at room temperature. Purify by size exclusion chromatography. For payload attachment, activate payload carboxylic acid with EDC/NHS in MES buffer at pH 5.5-6.5 for 15-30 minutes, then add antibody-linker conjugate and incubate at pH 7.2-8.0 for 2-4 hours. Analyze by SDS-PAGE or LC-MS.
|
| Cell Assay |
For cell-based experiments, prepare the ADC using the thiol conjugation and payload attachment protocols. Purify by size exclusion chromatography. Add to cultured cancer cells at 1-100 nM in complete medium. Incubate 24-72 hours at 37 degrees Celsius. Assess cytotoxicity by MTT or CCK-8 assay. For lysosomal cleavage, treat cells with cathepsin B inhibitor and evaluate the effect on cytotoxicity. Confirm target specificity by comparing antigen-positive and antigen-negative cell lines.
|
| Animal Protocol |
For in vivo studies, formulate the ADC in a suitable vehicle such as PBS or saline. Administer to mice via intravenous injection at 1-10 mg/kg every 2-3 days for 2-4 weeks in tumor xenograft models. Measure tumor volume twice weekly. Monitor body weight and clinical signs for toxicity. At study endpoint, excise tumors for immunohistochemistry and collect blood for pharmacokinetic analysis. All procedures follow IACUC-approved protocols.
|
| References |
| Molecular Formula |
C31H46N8O8
|
|---|---|
| Molecular Weight |
658.745747089386
|
| Exact Mass |
658.343
|
| CAS # |
1616727-20-8
|
| Related CAS # |
MC-VC-PAB-NH2 TFA;1616727-21-9
|
| PubChem CID |
90275566
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.5
|
| tPSA |
244
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
47
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)[C@@H](C(=O)N[C@@H](CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)COC(=O)NCCN)NC(=O)CCCCCN2C(=O)C=CC2=O
|
| InChi Key |
CNKMVFCYQSFWSZ-HOFKKMOUSA-N
|
| InChi Code |
InChI=1S/C31H46N8O8/c1-20(2)27(38-24(40)8-4-3-5-18-39-25(41)13-14-26(39)42)29(44)37-23(7-6-16-34-30(33)45)28(43)36-22-11-9-21(10-12-22)19-47-31(46)35-17-15-32/h9-14,20,23,27H,3-8,15-19,32H2,1-2H3,(H,35,46)(H,36,43)(H,37,44)(H,38,40)(H3,33,34,45)/t23-,27-/m0/s1
|
| Chemical Name |
[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-(2-aminoethyl)carbamate
|
| Synonyms |
MCVCPABNH2; MC VC PAB NH2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5180 mL | 7.5901 mL | 15.1803 mL | |
| 5 mM | 0.3036 mL | 1.5180 mL | 3.0361 mL | |
| 10 mM | 0.1518 mL | 0.7590 mL | 1.5180 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.